Medline Inc. (MDLN) Stock Price & How to Invest

Medline makes and distributes the unglamorous consumables that hospitals, surgery centers, physician offices, and nursing homes go through every single day: gloves, gowns, surgical kits, wound care, incontinence products, exam-room supplies, and diagnostics. It reports in two segments. Medline Brand covers products the company manufactures and sells under its own label (surgical solutions, front-line care, laboratory and diagnostics), and it carries the better margin. Supply Chain Solutions distributes third-party manufacturers' brands and runs the prime-vendor logistics contracts that put Medline trucks on a health system's loading dock several times a week. Roughly 90 percent of revenue is domestic. The company employs about 45,000 people and is headquartered in Northfield, Illinois.

The investment picture is a scale story wrapped around a thin net margin. Trailing revenue is about $29.9 billion, up roughly 12 percent, but trailing net income is only about $693 million, so a few hundred million dollars of one-time cost swings the reported bottom line hard. That is exactly what happened in the first half of 2026: a fire at the Tracy, California distribution center cost about $336 million before insurance, tariff refunds and repayments moved figures in both directions, and the company began spending on quality remediation after three FDA warning letters. Management raised its organic sales growth guidance and cut its adjusted EBITDA guidance in the same August 2026 release, which is a fair summary of the whole setup: demand is fine, execution is the question. The 2021 leveraged buyout by Blackstone, Carlyle, and Hellman & Friedman still shapes the balance sheet (net debt around $10.1 billion, roughly 2.9 times adjusted EBITDA) and the share register, since those sponsors have been selling into secondary offerings since the lockup lapsed.

The clearest near-term risk is regulatory. As of late June 2026 Medline had received three FDA warning letters covering facilities in Northfield, Illinois, Glens Falls, New York, and Waukegan, Illinois, with the Waukegan letter calling certain drug products adulterated after Bacillus cereus turned up in finished product samples on nine separate occasions between June 2023 and August 2025. Remediation costs money, can interrupt supply from specific plants, and invites further inspection. Second, the net margin is thin enough (roughly 2 percent trailing) that operational shocks like the Tracy distribution center fire, which cost about $336 million before insurance in the first half with another $50 million to $100 million expected in the second, dominate reported earnings even when the underlying business is fine. Third, tariffs and freight costs pass through a global sourcing base with a lag, and the second quarter figure was flattered by about $243 million of tariff refunds that will not repeat. Fourth, hospital group purchasing organizations negotiate hard and Cardinal Health, McKesson, and Owens & Minor all want the same shelf space. Finally, Blackstone, Carlyle, and Hellman & Friedman still hold a large block and have already run one $3.6 billion secondary at $41 per share, so supply overhang is a live factor in how the shares trade. Several shareholder law firms announced investigations following the FDA disclosure.

26 analysts publish price targets on MDLN, averaging $50.65 against a $36.66 price as of August 2026, or +38.2%. The published targets run from $40.00 to $62.00, a moderate spread, and the ratings split 22 buy, 4 hold, 0 sell. Over the last six months there have been 4 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MDLN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Medline Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Prime-vendor contracts in Supply Chain Solutions. The distribution segment grew about 16.3 percent in the June 2026 quarter to roughly $4.1 billion, well ahead of the manufactured-brand side. The most optimistic published target, $62.00, assumes this works close to its best case.

The case against. The clearest near-term risk is regulatory. The most pessimistic target, $40.00, is roughly what MDLN is worth if this bites instead.

Read the full bull and bear case on MDLN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Medline Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$29.9B, up ~12%
• Q2 2026 net sales: ~$7.7B, up ~11.6%
• Gross margin (TTM): ~26%
• Net income (TTM): ~$693M, down ~45%
• Market cap: ~$48B
• Net debt / leverage: ~$10.1B, ~2.9x adjusted EBITDA

The trailing P/E near 46 times looks expensive until you notice that trailing net income is depressed by the Tracy fire, quality remediation spend, and post-IPO charges, which is why the market watches adjusted EBITDA instead. On enterprise value of roughly $58 billion against full-year adjusted EBITDA guidance of $3.3 to $3.4 billion, the multiple sits around 17 times. That guidance was cut from $3.5 to $3.6 billion in the August 2026 release even as organic growth guidance went up to 9 to 10 percent, and the shares fell roughly 13 percent on the day. Medline does not pay a dividend.

Other names that sit close to MDLN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MDLN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MDLN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MDLN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Medline is a genuinely dominant, non-cyclical supplier whose top line keeps compounding, but the stock's near-term path runs through quality remediation, a warehouse fire, and a private-equity ownership block that is still selling down.

Whether MDLN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MDLN a buy or a sell?, and where the stock could go from here in the MDLN stock forecast.

For income investors, whether MDLN pays a dividend and how the payout looks is covered in does MDLN pay a dividend? And to weigh MDLN against a peer, read the full side-by-side comparisons: MDLN vs MCK and MDLN vs COSM.